172 related articles for article (PubMed ID: 30636774)
1. Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer.
Varkaris A; Katsiampoura A; Davis JS; Shah N; Lam M; Frias RL; Ivan C; Shimizu M; Morris J; Menter D; Overman M; Tran H; Heymach J; Chun YS; Vauthey JN; Calin G; Kopetz S
Br J Cancer; 2019 Feb; 120(3):340-345. PubMed ID: 30636774
[TBL] [Abstract][Full Text] [Related]
2. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and Predictive Value of Circulating Inflammation Signature in Non-Metastatic Nasopharyngeal Carcinoma: Potential Role for Individualized Induction Chemotherapy.
Lv SH; Li WZ; Liang H; Liu GY; Xia WX; Xiang YQ
J Inflamm Res; 2021; 14():2225-2237. PubMed ID: 34079329
[TBL] [Abstract][Full Text] [Related]
4. Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancer.
Imaoka H; Toiyama Y; Fujikawa H; Hiro J; Saigusa S; Tanaka K; Inoue Y; Mohri Y; Mori T; Kato T; Toden S; Goel A; Kusunoki M
Ann Oncol; 2016 Oct; 27(10):1879-86. PubMed ID: 27502702
[TBL] [Abstract][Full Text] [Related]
5. Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients.
Ji D; Qiao M; Yao Y; Li M; Chen H; Dong Q; Jia J; Cui X; Li Z; Xia J; Gu J
EBioMedicine; 2018 Sep; 35():189-197. PubMed ID: 30166271
[TBL] [Abstract][Full Text] [Related]
6. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum YKL-40, IL-6, CRP, CEA, and CA19-9 combined as a prognostic biomarker panel after resection of colorectal liver metastases.
Peltonen R; Gramkow MH; Dehlendorff C; Osterlund PJ; Johansen JS; Isoniemi H
PLoS One; 2020; 15(8):e0236569. PubMed ID: 32756596
[TBL] [Abstract][Full Text] [Related]
8. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer.
Toiyama Y; Hur K; Tanaka K; Inoue Y; Kusunoki M; Boland CR; Goel A
Ann Surg; 2014 Apr; 259(4):735-43. PubMed ID: 23982750
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review.
Yang C; Zou K; Zheng L; Xiong B
BMC Cancer; 2017 Nov; 17(1):725. PubMed ID: 29115932
[TBL] [Abstract][Full Text] [Related]
10. Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer.
Maierthaler M; Benner A; Hoffmeister M; Surowy H; Jansen L; Knebel P; Chang-Claude J; Brenner H; Burwinkel B
Int J Cancer; 2017 Jan; 140(1):176-187. PubMed ID: 27632639
[TBL] [Abstract][Full Text] [Related]
11. MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer.
Miyoshi J; Toden S; Yoshida K; Toiyama Y; Alberts SR; Kusunoki M; Sinicrope FA; Goel A
Sci Rep; 2017 Mar; 7():43393. PubMed ID: 28262692
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer.
Kwon KA; Kim SH; Oh SY; Lee S; Han JY; Kim KH; Goh RY; Choi HJ; Park KJ; Roh MS; Kim HJ; Kwon HC; Lee JH
BMC Cancer; 2010 May; 10():203. PubMed ID: 20465852
[TBL] [Abstract][Full Text] [Related]
13. Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.
Ulivi P; Canale M; Passardi A; Marisi G; Valgiusti M; Frassineti GL; Calistri D; Amadori D; Scarpi E
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29361687
[TBL] [Abstract][Full Text] [Related]
14. Circulating Exosomal MicroRNA-21 as a Biomarker in Each Tumor Stage of Colorectal Cancer.
Tsukamoto M; Iinuma H; Yagi T; Matsuda K; Hashiguchi Y
Oncology; 2017; 92(6):360-370. PubMed ID: 28376502
[TBL] [Abstract][Full Text] [Related]
15. Serum small RNAs in metastatic colorectal cancer predict response to chemotherapy and characterize high-risk patients.
Mjelle R; Kristensen AK; Tora S Solheim ; Westvik GS; Elvebakken H; Hofsli E
Mol Cancer; 2024 Jun; 23(1):133. PubMed ID: 38937787
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
[No Abstract] [Full Text] [Related]
17. Inhibition of miR-15b decreases cell migration and metastasis in colorectal cancer.
Li J; Chen Y; Guo X; Zhou L; Jia Z; Tang Y; Lin L; Liu W; Ren C
Tumour Biol; 2016 Jul; 37(7):8765-73. PubMed ID: 26743779
[TBL] [Abstract][Full Text] [Related]
18. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment.
Kjersem JB; Ikdahl T; Lingjaerde OC; Guren T; Tveit KM; Kure EH
Mol Oncol; 2014 Feb; 8(1):59-67. PubMed ID: 24119443
[TBL] [Abstract][Full Text] [Related]
19. Elevated expression of miR-24-3p is a potentially adverse prognostic factor in colorectal adenocarcinoma.
Kerimis D; Kontos CK; Christodoulou S; Papadopoulos IN; Scorilas A
Clin Biochem; 2017 Apr; 50(6):285-292. PubMed ID: 27939727
[TBL] [Abstract][Full Text] [Related]
20. Post-chemotherapeutic CEA and CA19-9 are prognostic factors in patients with colorectal liver metastases treated with hepatic resection after oxaliplatin-based chemotherapy.
Sakamoto Y; Miyamoto Y; Beppu T; Nitta H; Imai K; Hayashi H; Baba Y; Yoshida N; Chikamoto A; Baba H
Anticancer Res; 2015 Apr; 35(4):2359-68. PubMed ID: 25862901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
